Topical Treatment for TMJ Arthralgia

• Status: Not yet recruiting
• Trial end date: 2025-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this clinical trial is to evaluate the efficacy of topical 2.5% hydrocortisone in TMJ arthralgia. The main questions it aims to answer are:

• How does pain reduction compare?

• How does improvement in jaw function limitation compare?

• How do side effects compare? Participants will

• On day 1 be examined and report their pain level and jaw function limitation

• On days 1-21, apply their cream four times a day

• On day 21, report their pain level, jaw function limitation, compliance with instructions, and side effects.

Researchers will compare topical 2.5% hydrocortisone and topical 1% diclofenac to see if efficacy and side effects differ.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of the Pacific
• Treatments: Diclofenac; Hydrocortisone

Criteria

Inclusion Criteria:

• Arthralgia of at least 1 TMJ for at least 3 days

Exclusion Criteria:

• Systemic pain condition

• Past adverse reaction to steroid

• Currently taking steroid

• Taken steroid in the past ___ months

• Muscle relaxants (may start after study is complete)

• New night guard during study, or within 1 month of start of study (may start after study is complete)